CD40 and neoplasm: This suggests that agonistic CD40 antibody therapy not only remodels the tumor microenvironment by promoting pro-inflammatory and antitumor immune responses but also effectively suppresses oncogenic signaling, ultimately inhibiting tumor progression and improving survival outcomes.